1. Alexander, H. R., Bartlett, D. L., Libutti, S. K., Fraker, D. L., Moser, T. & Rosenberg, S. A. (1998) Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 12: 1479–1489.
2. Asher, A. L., Mule, J. J., Reichert, C. M., Shiloni, E. & Rosenberg, S. A. (1987) Studies of the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138: 963–974.
3. Benckhuijsen, C., Kroon, B. B. R., Van Geel, A. N. & Wieberdink, J. (1988) Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 14: 157–163.
4. Borel Rinkes, I. H. M., de Vries, M. R., Jonker, A. M., Swaak, T. J. G., Hack, C. E., Nooijen, PTGA, Wiggers, T. & Eggermont, A. M. M. (1997) Isolated hepatic perfusion in the pig with TNF-α with and without melphalan. Br J Cancer 75: 1447–1453.
5. Broukaert, P., Libert, C., Everaerdt, B. & Fiers, W. (1992) Selective species specificity of tumor necrosis factor for toxicity in the mouse. Lymphokine Cytokine Res 11: 193–196.